Thursday May 25th 2017

Posts Tagged ‘News’

Medicare Advantage plan members may switch to Original Medicare during the annual disenrollment period Jan 1 to Feb 14

Medicare Advantage plan members may switch to Original Medicare during the annual disenrollment period Jan 1 to Feb 14

Recent changes to the provider networks of certain Medicare Advantage plans (private Medicare managed care plans) are reported to be causing concern within the MS community. Medicare Advantage (MA) plan members are reminded that they have options if they are dissatisfied [Read More]

Lastest Multiple Sclerosis News

Lastest Multiple Sclerosis News

As Genzyme waits for FDA ruling, its multiple sclerosis drug wins approval in … As Cambridge biotech Genzyme awaits an upcoming US regulatory decision on its experimental multiple sclerosis drug, the medicine has won approval for sale in Canada. Genzyme said Friday [Read More]

New Studies Look at Lifestyle Factors in Terms of Who Gets MS and Improving the Daily Lives of People with MS

New Studies Look at Lifestyle Factors in Terms of Who Gets MS and Improving the Daily Lives of People with MS

One of the National Multiple Sclerosis Society’s priorities is to drive research on wellness and lifestyle, where advancements can change quality of life with MS on a daily basis. [Read More]

 Page 1 of 2  1  2 »

Latest Topics

MS Study Alert: Share Your Thoughts About MS Research

MS Study Alert: Share Your Thoughts About MS Research

/About-the-Society/News/MS-Study-Alert-Share-Your-Thoughts-About-MS-Resea [Read More]

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

Mallinckrodt begins enrolment in Phase IV trial of HP Acthar gel for RRMS

UK-based specialist pharmaceutical firm Mallinckrodt has begun patient enrolment in the Phase IV OPTIONS clinical trial [Read More]

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

First Results Announced from Second Phase III Trial of Oral Ozanimod in People with Relapsing MS

/About-the-Society/News/First-Results-Announced-from-Second-Phase-III-Tria [Read More]

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Experimental treatment tempers HLH, MS symptoms in mouse models, study shows

Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of [Read More]

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of [Read More]